H.C. Wainwright Maintains a Buy on Esperion Therapeutics (ESPR), Keeps the PT

Esperion Therapeutics, Inc. (NASDAQ:ESPR) is one of the Best Rising Penny Stocks to Buy According to Hedge Funds. On August 5, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion Therapeutics, Inc. (NASDAQ:ESPR) with a price target of $16.

The analyst noted that the company delivered robust performance during its fiscal second quarter of 2025 and beat Wall Street estimates for revenue and EPS. The company delivered a revenue of $82.39 million, reflecting 11.58% year-over-year growth and ahead of estimates by $19.34 million. The EPS of negative $0.02 also topped the consensus by $0.14.

H.C. Wainwright Maintains a Buy on Esperion Therapeutics (ESPR), Keeps the PT

Pantginis highlighted that Esperion Therapeutics, Inc. (NASDAQ:ESPR) saw a huge jump in US product revenue, especially from its NEXLETOL and NEXLIZET drugs. This was mainly driven by more retail prescriptions and higher use among patients who cannot tolerate statins.

Moreover, the company is also expanding globally and has secured approval for its BDA product in 40 countries, with more approvals expected soon.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) develops and sells oral, once-daily, non-statin medicines for people at risk of cardiovascular disease with high LDL cholesterol.

While we acknowledge the potential of ESPR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ESPR and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.